Outlook Therapeutics Names Clinical SVP

Jennifer M. Kissner, Ph.D. has been appointed senior vice president, Clinical Development, Outlook Therapeutics, Inc.

Dr. Kissner has extensive experience in therapeutic product development from the benchtop through clinical development and regulatory filing, including small molecules, biologics, gene therapy and devices, across multiple therapeutic areas, specifically working in the retina space for 12 years.  She also brings global experience leading development programs across the US , EU and Asia Pacific regions.  Most recently, Dr. Kissner was vice president, Clinical Development at Clearside Biomedical where she led global clinical development for a platform technology.  Previously, she was director, Clinical Development at Acucela and held increasing roles of responsibility in Retina Development at Alcon.

"We would like to extend a warm welcome to Jennifer and are excited that she has joined the Outlook team," said Terry Dagnon, Chief Operating Officer at Outlook Therapeutics. "Dr. Kissner’s extensive clinical development expertise, specializing in wet AMD and other retina diseases, will be an important asset to Outlook Therapeutics as we continue to advance the ONS-5010 program."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.